胰腺手术患者伴与不伴慢性胰腺炎的纤维化比较评估
该研究回顾性分析了2004至2023年间接受不同胰腺手术的患者,包括24例浆液性囊腺瘤对照、31例不确定慢性胰腺炎(CP)、36例复发性急性胰腺炎(RAP)和115例明确CP,采用Ammann纤维化评分(FS)评估手术病理标本。结果显示中位FS在对照组、不确定CP、RAP和明确CP中分别为0.33、2.8、6.5和8.5,各组间差异显著;结论提示纤维化定量可能为胰腺炎连续谱的评估提供补充信息,当前不确定CP的诊断标准若以纤维化为金标准可能导致过度诊断。
要点
- 中位纤维化评分从对照0.33递增至明确CP的8.5,各组间差异显著。
- 纤维化评分与急性胰腺炎发作次数无关。
核心结论
- 纤维化定量可能为胰腺炎连续谱的临床、影像和功能评估提供补充信息。
- 当前不确定CP的诊断标准若以纤维化为金标准可能导致过度诊断。
- 遗传性或特发性RAP发作≥7次者纤维化程度与CP相似。
研究设计与样本
- 回顾性研究,纳入2004至2023年接受胰腺手术的患者。
- 共206例:对照组24例(浆液性囊腺瘤行远端胰腺切除术),不确定CP 31例,RAP 36例,明确CP 115例。
- 明确和不确定CP按M-ANNHEIM标准定义,RAP定义为≥2次影像学证实的急性胰腺炎发作。
- 所有手术病理标本采用Ammann纤维化评分(FS)评估。
主要发现
- 中位FS(IQR):对照组0.33(0.2-0.5),不确定CP 2.8(1-6),RAP 6.5(3.7-8),明确CP 8.5(5.9-11)。
- 事后Dunn检验(Holm校正)显示所有诊断组间总FS差异显著,多数成分评分组间也差异显著。
- FS与急性胰腺炎发作次数无相关性。
关键数值与推荐
- 明确和不确定CP采用M-ANNHEIM标准定义。
- RAP定义为≥2次影像学证实的急性胰腺炎发作。
- 纤维化评估采用Ammann纤维化评分(FS)。
临床怎么用
- 在评估胰腺炎连续谱患者时,可考虑纤维化定量作为临床、影像和功能评估的补充。
- 对不确定CP的诊断需谨慎,避免仅凭现行标准过度诊断。
- 遗传性或特发性RAP发作≥7次者应关注纤维化进展,类似CP管理。
局限性
- 回顾性研究设计。
- 样本来自手术患者,可能存在选择偏倚。
- 对照组为浆液性囊腺瘤患者,非完全健康人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Fibrosis is considered the gold standard for diagnosing chronic pancreatitis (CP) but has not been systematically studied across a large cohort of patients with and without pancreatitis undergoing different pancreatic surgeries. METHODS: Demographic, clinical, and radiologic data for patients undergoing total pancreatectomy with islet autotransplantation for indeterminate CP, recurrent acute pancreatitis (RAP), and definite CP; Whipple/Frey for indeterminate and definite CP; and distal pancreatectomy for serous cystadenoma between 2004 and 2023 were reviewed. Definite and indeterminate CP were defined by M-ANNHEIM criteria; and RAP defined as ≥2 episodes of imaging-documented acute pancreatitis. The Ammann Fibrosis Score (FS) was tabulated for all surgical pathology specimens. Patients with serous cystadenoma were included as controls. Data were summarized as median (interquartile range [IQR]) or number (%). RESULTS: There were 206 patients including 24 controls, 31 with indeterminate CP, 36 with RAP, and 115 with definite CP. The median FS was 0.33 (IQR, 0.2-0.5), 2.8 (IQR, 1-6), 6.5 (IQR, 3.7-8), and 8.5 (IQR, 5.9-11) in controls, indeterminate CP, RAP, and definite CP, respectively. Post hoc Dunn tests with Holm adjustment showed significant differences in total FS across all diagnostic groups, with most component scores also differing significantly between groups. There was no correlation between FS and number of AP episodes; however, patients with genetic or idiopathic RAP with ≥7 episodes of AP had similar FS to genetic or idiopathic CP (P = .08). CONCLUSIONS: Fibrosis quantification may provide complementary information to existing clinical, imaging, and functional assessments when evaluating patients across the pancreatitis continuum. Current diagnostic criteria for indeterminate CP are leading to an overdiagnosis of CP if fibrosis remains the criteria standard. Among genetic/idiopathic etiologies, patients with RAP with ≥7 episodes of AP have similar quantities of fibrosis to CP.
引用
- Metri AA, Faghih M, Afghani E, et al. A Comparative Evaluation of Fibrosis in Patients With and Without Chronic Pancreatitis Undergoing Pancreatic Surgery. Clin Gastroenterol Hepatol. 2026. PMID: 42660256. doi:10.1016/j.cgh.2026.08.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。